Document is current
Any future updates will be listed below
-
Authors
Rath, Jan A.
Rudden, Lucas S. P. https://orcid.org/0000-0002-4753-8890
Nouraee, Nazila
Que, Tiffany X. Y.
Von Gunten, Christine
Perez, Cynthia
Birch, Flora
Bhugowon, Yashashvi
Fueglistaler, Andreas https://orcid.org/0000-0001-6448-5981
Chatzi Souleiman, Aisima https://orcid.org/0000-0003-2471-0296
Barth, Patrick https://orcid.org/0000-0002-0744-6844
Arber, Caroline https://orcid.org/0000-0001-6440-9970
- License Information
-
More Information
Article History
Received: 26 January 2024
Accepted: 2 September 2025
First Online: 28 October 2025
Competing interests
: P.B. holds patents in the field of protein engineering. C.A. holds patents in the field of engineered T cell therapies. C.A. and P.B. hold patents and provisional patent applications in the field of engineered T cell therapies. J.A.R. and L.S.P.R. hold a provisional patent application in the field of engineered T cell therapies. C.A. receives licensing fees and royalties from Immatics (through previous institution Baylor College of Medicine), participated in advisory boards for Kite/Gilead, Janssen and Celgene/BMS, and received sponsored travel from Gilead (through current institution University Hospital Lausanne). The other authors declare no competing interests.
